Somewhat Favorable Media Coverage Extremely Likely to Impact Salix Pharmaceuticals (SLXP) Stock Price
News stories about Salix Pharmaceuticals (NASDAQ:SLXP) have trended somewhat positive on Thursday, according to AlphaOne Sentiment Analysis. AlphaOne, a division of Accern, identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Salix Pharmaceuticals earned a coverage optimism score of 0.12 on AlphaOne’s scale. AlphaOne also gave press coverage about the specialty pharmaceutical company an impact score of 93 out of 100, indicating that recent press coverage is extremely likely to have an impact on the stock’s share price in the near term.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Extremely Likely to Impact Salix Pharmaceuticals (SLXP) Stock Price” was posted by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/05/04/somewhat-favorable-media-coverage-extremely-likely-to-impact-salix-pharmaceuticals-slxp-stock-price.html.
About Salix Pharmaceuticals
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others.
Receive News & Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.